NAD(P)H:quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer

Cui,Xuelian; Jin,Tiefeng; Wang,Xiaoyan; Jin,Guang; Li,Zhuhu; Lin,Lijuan

doi:10.3892/or.2014.3494

NAD(P)H:quinone oxidoreductase-1 overexpression predicts poor prognosis in small cell lung cancer

Authors:
- Xuelian Cui
- Tiefeng Jin
- Xiaoyan Wang
- Guang Jin
- Zhuhu Li
- Lijuan Lin
View Affiliations

Affiliations: Department of Pathology, Yanbian University College of Medicine, Yanji, Jilin 133002, P.R. China
Published online on: September 17, 2014 https://doi.org/10.3892/or.2014.3494
Pages: 2589-2595

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

NAD(P)H:quinone oxidoreductase-1 (NQO1) is commonly elevated in various types of human cancers, including pancreatic, breast and thyroid cancer, as well as others. However, little is known concerning the status of NQO1 in small cell lung cancer (SCLC). To investigate the clinicopathological significance of NQO1 expression and evaluate its role as a potential prognostic marker in SCLC, protein and mRNA expression levels of NQO1 were determined in four fresh tissue samples of SCLC and paired adjacent non-cancerous tissues using western blotting and real-time qRT-PCR, respectively, and 115 cases of SCLC with strict follow-up were selected for immunohistochemical (IHC) staining of NQO1 protein. The correlation between NQO1 expression and the clinicopathological features of SCLC was evaluated using the Chi-square (χ2) and Fisher's exact tests, survival rates were calculated using the Kaplan-Meier method, and univariate and multivariate analyses were performed using the Cox proportional hazards regression model. In regards to the results, levels of NQO1 protein and mRNA were significantly elevated in the four fresh tissue samples of SCLC compared with levels in the paired adjacent non-cancerous tissues, respectively. IHC analysis showed that the rate of strong positive NQO1 protein expression was significantly higher (48.70%) in SCLC when compared with the rate in either adjacent non-cancerous or normal lung tissues (both P<0.001). The rate of strong positive NQO1 protein expression was correlated with large tumor size (P=0.019), late pathologic stage (P=0.001) and the presence of lymph node metastasis (P=0.001). Moreover, high‑level expression of NQO1 protein was significantly correlated with lower disease-free survival (P=0.001) and 5-year survival rates (P<0.001) in SCLC patients, particularly early‑stage patients (P=0.045 and P=0.033, respectively). Further Cox analysis revealed that NQO1 expression emerged as a significantly independent hazard factor for the 5-year survival rate of patients with SCLC (P=0.042). In conclusion, NQO1 plays an important role in the progression of SCLC, and it may potentially be used as a biomarker and therapeutic target of SCLC.

View Figures

View References

1	Kallianos A, Rapti A, Zarogoulidis P, et al: Therapeutic procedure in small cell lung cancer. J Thorac Dis. 5(Suppl 4): S420–S424. 2013.
2	Rudin CM, Hann CL, Peacock CD and Watkins DN: Novel systemic therapies for small cell lung cancer. J Natl Compr Cancer Netw. 6:315–322. 2008.PubMed/NCBI
3	Zhang Y and He J: The development of targeted therapy in small cell lung cancer. J Thorac Dis. 5:538–548. 2013.PubMed/NCBI
4	Siegel D and Ross D: Immunodetection of NAD(P)H:quinine oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med. 29:246–253. 2000.
5	Siegel D, Yan C and Ross D: NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol. 83:1033–1040. 2012. View Article : Google Scholar : PubMed/NCBI
6	Zhu CL, Huang Q, Liu CH, et al: NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T gene polymorphism association with digestive tract cancer: a meta-analysis. Asian Pac J Cancer Prev. 14:2349–2354. 2013. View Article : Google Scholar : PubMed/NCBI
7	Buranrat B, Prawan A, Kukongviriyapan U, et al: Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. World J Gastroenterol. 16:2362–2370. 2010. View Article : Google Scholar : PubMed/NCBI
8	Lyn-Cook BD, Yan-Sanders Y, Moore S, et al: Increased levels of NAD(P)H: quinine oxidoreductase 1 (NQO1) in pancreatic tissues from smokers and pancreatic adenocarcinomas: a potential biomarker of early damage in the pancreas. Cell Biol Toxicol. 22:73–80. 2006. View Article : Google Scholar : PubMed/NCBI
9	Cheng Y, Li J, Martinka M and Li G: The expression of NAD(P)H:quinone oxidoreductase 1 is increased along with NF-κB p105/p50 in human cutaneous melanomas. Oncol Rep. 23:973–979. 2010.
10	Awadallah NS, Dehn D, Shah RJ, et al: NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol. 16:24–31. 2008.PubMed/NCBI
11	Garate M, Wani AA and Li G: The NAD(P)H:quinone oxido-reductase 1 induces cell cycle progression and proliferation of melanoma cells. Free Radic Biol Med. 48:1601–1609. 2010. View Article : Google Scholar : PubMed/NCBI
12	Liu S, Li L, Zhang Y, et al: The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells. J Biol Chem. 287:30228–30239. 2012. View Article : Google Scholar : PubMed/NCBI
13	Kong J, Li Y, Liu S, et al: High expression of ezrin predicts poor prognosis in uterine cervical cancer. BMC Cancer. 13:5202013. View Article : Google Scholar : PubMed/NCBI
14	Lin L, Piao J, Gao W, et al: DEK over expression as an independent biomarker for poor prognosis in colorectal cancer. BMC Cancer. 13:3662013. View Article : Google Scholar : PubMed/NCBI
15	Lajin B and Alachkar A: The NQO1 polymorphism C609T (Pro187Ser) and cancer susceptibility: a comprehensive meta-analysis. Br J Cancer. 109:1325–1337. 2013. View Article : Google Scholar
16	Talalay P and Dinkova-Kostova AT: Role of nicotinamide quinine oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates. Methods Enzymol. 382:355–364. 2004. View Article : Google Scholar : PubMed/NCBI
17	Lee J, Kim KS, Lee MH, et al: NAD(P)H: quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 polymorphisms in papillary thyroid microcarcinoma: correlation with phenotype. Yonsei Med J. 54:1158–1167. 2013. View Article : Google Scholar : PubMed/NCBI
18	Nair S, Xu C, Shen G, et al: Pharmacogenomics of phenolic anti-oxidant butylated hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57L/6J mice. Pharm Res. 23:2621–2637. 2006. View Article : Google Scholar : PubMed/NCBI
19	Kuehl BL, Paterson JW, Peacock JW, et al: Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer. 72:555–561. 1995. View Article : Google Scholar : PubMed/NCBI
20	Schulz WA, Krummeck A, Rösinger I, et al: Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics. 7:235–239. 1997. View Article : Google Scholar : PubMed/NCBI
21	Nagata M, Kimura T, Suzumura T, et al: C609T polymorphism of NADPH quinone oxidoreductase 1 correlates clinical hematological toxicities in lung cancer patients treated with amrubicin. Clin Med Insights Oncol. 7:31–39. 2013.
22	Malik MA, Zargar SA and Mittal B: Role of NQO1 609C>T and NQO2 -3423G>A gene polymorphisms in esophageal cancer risk in Kashmir valley and meta analysis. Mol Biol Rep. 39:9095–9104. 2012.
23	Singh M, Goel S, Meeley RB, et al: Production of viable gametes without meiosis in maize deficient for an ARGONAUTE protein. Plant Cell. 23:443–458. 2011. View Article : Google Scholar : PubMed/NCBI
24	Soucek P, Susova S, Mohelnikova-Duchonova B, et al: Polymorphisms in metabolizing enzymes and the risk of head and neck squamous cell carcinoma in the Slavic population of the central Europe. Neoplasma. 57:415–421. 2010. View Article : Google Scholar : PubMed/NCBI
25	Mikami K, Naito M, Ishiguro T, et al: Immunological quantitation of DT-diaphorase in carcinoma cell lines and clinical colon cancers: advanced tumors express greater levels of DT-diaphorase. Jpn J Cancer Res. 89:910–915. 1998. View Article : Google Scholar
26	Fagerholm R, Sprott K, Heikkinen T, et al: Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer. Ann Oncol. 24:2780–2785. 2013. View Article : Google Scholar : PubMed/NCBI
27	Li LS, Bey EA, Dong Y, et al: Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy. Clin Cancer Res. 17:275–285. 2011.PubMed/NCBI
28	Vasiliou V, Ross D and Nebert DW: Update of the NAD(P) H:quinine oxidoreductase (NQO) gene family. Hum Genomics. 2:329–335. 2006. View Article : Google Scholar : PubMed/NCBI